PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NK/T-CELL LYMPHOMA OR NK-CELL LEUKEMIA, COMPRISING PHOSPHODIESTERASE TYPE 5 INHIBITOR

摘要

The present invention relates to: a pharmaceutical composition for preventing or treating NK/T-cell lymphoma, comprising a phosphodiesterase type 5 inhibitor, the pharmaceutical composition being for inhibiting the reactivation of the Epstein–Barr virus (EBV) induced by a HDAC inhibitor; an anticancer therapy adjuvant composition; and a health functional food. By using the pharmaceutical composition for preventing, alleviating or treating NK/T-cell lymphoma, according to the present invention, EBV reactivation, induced by a HDAC inhibitor used as an anticancer agent for NK/T-cell lymphoma, may be inhibited, and thus side-effects of the HDAC inhibitor may be reduced, and an anticancer effect may be notably increased. Thus, the present invention may be widely used in the pharmaceutical industry on the basis of said effects.